About: Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.45 (-8.46%)
CRBU NASDAQ Caribou Biosciences Inc
Caribou Biosciences Inc share price
Atividade de preço de CRBU
Último preço
$ 0,450
Variação (24h)
-0,04 USD (8,46%)
Volume
2.23M
Volume (média 4 sem.)
-
Abertura
$ 0,49
Variação do dia
$ 0,45 - $ 0,50
Fechamento anterior
$ 0,49
Último negócio
29 Oct, 6:42 pm GMT+0
Atrasado
29 Oct, 6:42 pm GMT+0
CRBU price performance
Atrasado
29 Oct, 6:42 pm GMT+0
quote.marketSignals